TY - JOUR
T1 - MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents
T2 - Gadolinium Retention and Nephrogenic Systemic Fibrosis
AU - McDonald, Jennifer S.
AU - McDonald, Robert J.
N1 - Funding Information:
J.S. McDonald and R.J. McDonald report research grants with GE Healthcare. R.J. McDonald report research grants with Bracco Imaging. J.S. McDonald and R.J. McDonald serve as scientific advisors for GE Healthcare.
Publisher Copyright:
© 2020 Elsevier Inc.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/11
Y1 - 2020/11
N2 - Gadolinium (Gd)-based contrast agents (GBCAs) have revolutionized of MR imaging, enabling physicians to obtain life-saving medical information that often cannot be obtained with unenhanced MR imaging or other imaging modalities. Since regulatory approval in 1988, more than 450 million intravenous GBCA doses have been administered worldwide, with an extremely favorable pharmacologic safety profile. Recent evidence has demonstrated, however, that a small fraction of Gd is retained in human tissues. No direct correlation between Gd retention and clinical effects has been confirmed; however, a subset of patients have attributed various symptoms to GBCA exposure. This review details current knowledge regarding GBCA safety.
AB - Gadolinium (Gd)-based contrast agents (GBCAs) have revolutionized of MR imaging, enabling physicians to obtain life-saving medical information that often cannot be obtained with unenhanced MR imaging or other imaging modalities. Since regulatory approval in 1988, more than 450 million intravenous GBCA doses have been administered worldwide, with an extremely favorable pharmacologic safety profile. Recent evidence has demonstrated, however, that a small fraction of Gd is retained in human tissues. No direct correlation between Gd retention and clinical effects has been confirmed; however, a subset of patients have attributed various symptoms to GBCA exposure. This review details current knowledge regarding GBCA safety.
KW - Gadolinium deposition disease
KW - Gadolinium retention
KW - Gadolinium-based contrast agents
KW - MR imaging contrast agent
KW - Nephrogenic systemic fibrosis
KW - Radiology safety
UR - http://www.scopus.com/inward/record.url?scp=85092268893&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092268893&partnerID=8YFLogxK
U2 - 10.1016/j.mric.2020.06.001
DO - 10.1016/j.mric.2020.06.001
M3 - Review article
C2 - 33040991
AN - SCOPUS:85092268893
SN - 1064-9689
VL - 28
SP - 497
EP - 507
JO - Magnetic Resonance Imaging Clinics of North America
JF - Magnetic Resonance Imaging Clinics of North America
IS - 4
ER -